{"links":{"html":"https://www.erudio.com/reports/bmt-ctn-0901-nct01339910","json":"https://www.erudio.com/reports/bmt-ctn-0901-nct01339910.json","markdown":"https://www.erudio.com/reports/bmt-ctn-0901-nct01339910.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"bmt-ctn-0901-01339910"}},"request":"https://www.erudio.com/contact?report=bmt-ctn-0901-01339910"},"offer":{"cited_commentary_sources":23,"verified_hcp_statements":91,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":24,"optional":true,"price_per_verified_person_usd":15,"price_usd":360,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"bmt-ctn-0901-nct01339910"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=bmt-ctn-0901-01339910","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/bmt-ctn-0901-nct01339910","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T03:20:51.877698Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":7,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":4,"title":"Primary endpoint: Percentage of Participants With Overall Survival (OS)"},{"claim_count":9,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":20,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":10,"title":"Population and setting"},{"claim_count":28,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":13,"title":"The comparison"},{"claim_count":15,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":6,"title":"Safety and tolerability"},{"claim_count":12,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":22,"coverage":"discussed","id":"A1","source_count":8,"title":"MRD-dependent intensity selection and assay interpretation"},{"claim_count":11,"coverage":"discussed","id":"A2","source_count":2,"title":"Immediate allo versus additional MRD-directed treatment"},{"claim_count":8,"coverage":"discussed","id":"A3","source_count":5,"title":"RICMAC, German AML comparisons and broader intensity classification"},{"claim_count":8,"coverage":"discussed","id":"A4","source_count":2,"title":"Maintenance, surveillance and patient support around transplantation"},{"claim_count":11,"coverage":"discussed","id":"A5","source_count":7,"title":"Evidence awareness, historical availability and research priorities"}],"counts":{"cited_sources":27,"claims_by_expression_type":{"comparison":6,"experience":5,"interpretation":13,"opinion":27,"primary_context":13,"question":3,"restatement":18,"uncertainty":6},"claims_by_kind":{"limitation":1,"objective_result":1,"protocol_statement":12,"publication_statement":1,"source_observation":76},"clinician_statements":40,"evidence_units":69,"findings":6,"organisational_accounts":1,"people_cited":30,"people_identity_verified":24,"people_total":30,"screened_sources":42,"verified_claims":91},"findings_index":[{"id":"F1","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":0,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":8,"passages":10,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Better outcomes with MRD negativity do not establish that delaying transplantation to clear MRD helps"},{"id":"F2","structure":{"claims":24,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":3,"views":19},"has_counterview":true,"limitations":3,"links":{"context":2,"support":26},"ma_question":true,"named_voices":14,"passages":18,"sources":12,"sources_by_kind":{"commentary":10,"media":1,"publication":1}},"title":"The preference for MAC is conditional on fitness, with explicit concern about overextension to older patients"},{"id":"F3","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":3,"views":7},"has_counterview":true,"limitations":3,"links":{"context":2,"support":13},"ma_question":true,"named_voices":7,"passages":10,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"MRD-dependent intensity choices attract interest, but the statements do not support blanket equivalence"},{"id":"F4","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":2,"questions":3,"restated":4,"views":4},"has_counterview":false,"limitations":3,"links":{"context":0,"support":15},"ma_question":true,"named_voices":4,"passages":7,"sources":4,"sources_by_kind":{"commentary":1,"media":3}},"title":"MRD assessment is valued, while assay comparability and the evidence needed to act remain unsettled"},{"id":"F5","structure":{"claims":16,"claims_by_group":{"comparisons":3,"experience":1,"questions":0,"restated":6,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":17},"ma_question":true,"named_voices":8,"passages":10,"sources":8,"sources_by_kind":{"commentary":5,"media":2,"publication":1}},"title":"Endpoint choice, statistical power and regimen classification complicate reconciliation across studies"},{"id":"F6","structure":{"claims":15,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":6,"views":7},"has_counterview":true,"limitations":4,"links":{"context":0,"support":15},"ma_question":true,"named_voices":3,"passages":6,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"Regimen-level toxicity, organ function and post-transplant support qualify the intensity decision"}],"medical_affairs_question":"How should Medical Affairs distinguish evidence for an MRD-informed conditioning choice from evidence for delaying transplantation to clear MRD, while keeping fitness, readiness and access explicit?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. MRD clearance versus proceeding directly to transplantation"},{"id":"section-2","level":2,"title":"2. MAC preference does not remove the fitness boundary"},{"id":"section-3","level":2,"title":"3. MRD-dependent conditioning is an interpretation, not a universal equivalence rule"},{"id":"section-4","level":2,"title":"4. Assay uncertainty limits how readily MRD can become an action rule"},{"id":"section-5","level":2,"title":"5. Apparent cross-trial inconsistency requires attention to the question actually tested"},{"id":"section-6","level":2,"title":"6. Intensity labels do not replace regimen-specific safety and follow-up considerations"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":2},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T1","label":"Primary endpoint: Percentage of Participants With Overall Survival (OS)"},{"findings":[{"id":"F2","shared_claims":6},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":4}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":15},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":5}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":13},{"id":"F3","shared_claims":6},{"id":"F5","shared_claims":5},{"id":"F6","shared_claims":8}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":8},{"id":"F6","shared_claims":9}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":10}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T03:20:51.877698Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T03:32:53Z","record_hash":"322c33dc4f07919057fbac6c88e8d962df5dc052b16e623e44a8b323c04a0d03","release_hash":"f5ae87d63678b5a7e28963ca8c6b546e9d55fffe990f89489fe71f1033d8c6f9","report_id":"erudio-nct01339910","run_id":"edf268f0-fae7-40ee-a796-4fd1ec9d6c2e","schema_version":"5.0","slug":"bmt-ctn-0901-01339910","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"BMT CTN 0901 compares myeloablative with reduced-intensity conditioning before donor transplantation, asking which improves survival in adults with AML or MDS. Commentary comes from X posts, a podcast and YouTube interviews, including medical oncologists with confirmed clinical roles. The discussion turns on when fitness supports myeloablative conditioning in older patients, unresolved questions about MRD assays for intensity selection, and disagreement over delaying transplantation to clear residual disease.","meta_description":"42 sources screened · 91 verified statements (40 from clinicians verified by NPI or staff page) from 27 sources · 6 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-33808e42da9d90402884"],"id":"F5","paraphrase":"An X post asks how to reconcile long-term findings from another AML conditioning study with BMT CTN 0901.","publication_caveats":{"reason":"Publication caveats are not specified for this source.","status":"not_set"},"source_channel":"x_thread","source_date":"2018-03-15","title":"Endpoint choice, statistical power and regimen classification complicate reconciliation across studies"},{"cited_claim_ids":["claim-0f678899d0023b822225"],"id":"F4","paraphrase":"A YouTube interview explores whether a laboratory analysis added to BMT CTN 0901 could identify patients at higher relapse risk after reduced-intensity transplantation.","publication_caveats":{"reason":"Publication caveats are not specified for this source.","status":"not_set"},"source_channel":"youtube","source_date":"2019-07-16","title":"MRD assessment is valued, while assay comparability and the evidence needed to act remain unsettled"}]},"publication":{"approved_at":"2026-10-31T03:32:53Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":42},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a question about transplant consolidation selection based on fitness, prior therapy, donor availability and residual disease testing.","Not yet captured in this edition: a question about transplant conditioning selection in AML with prior refractory disease, persistent fungal lung cavities and a matched sibling donor.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","29 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","This edition describes the sources reviewed, not the prevalence of views among HCPs or a professional consensus. Reposts and relayed presentations are not independent endorsements.","Some potentially relevant passages were not fully assessed. Discussions without the trial's name or identifier, or using different transcriptions, may be missing.","Full text was unavailable for two referenced publications. The primary results abstract was available, but detailed long-term and MRD interpretations here rely substantially on attributed commentary.","Several brief replies lack the proposition or answer option needed to determine a specific clinical recommendation.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The a YouTube channel interview's spoken passages cannot be assigned to a named person from the available evidence.","The statements come from different dates and clinical exchanges. Their order does not establish a change of mind, and historical statements about unavailable evidence are not current statements of absence.","Only some interventions were checked for regulatory information, and exact combination labels were not located. No conclusion about regulatory status or absence of an applicable label can be drawn."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":1,"registry":3,"regulatory":0,"x_thread":20,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":23,"methods":3,"results":1},"count":27,"evidence_window":{"end":"2026-08-20","start":"2015-09-19"},"retrieval_snapshot":"2026-10-31T02:44:32.946885Z","timeline":[{"count":1,"week":"2015-W38"},{"count":1,"week":"2015-W50"},{"count":1,"week":"2016-W11"},{"count":2,"week":"2018-W11"},{"count":1,"week":"2019-W09"},{"count":1,"week":"2019-W24"},{"count":1,"week":"2019-W29"},{"count":1,"week":"2019-W41"},{"count":1,"week":"2020-W12"},{"count":1,"week":"2021-W09"},{"count":1,"week":"2021-W31"},{"count":1,"week":"2021-W40"},{"count":1,"week":"2022-W21"},{"count":1,"week":"2022-W45"},{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W17"},{"count":1,"week":"2024-W08"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W02"},{"count":1,"week":"2025-W41"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W34"}],"undated_sources":4},"quote_policies":[{"id":"clinicaltrials:NCT01339910:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT01339910:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT01339910:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT01339910:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT01339910:sap:2","quote_policy":"short_quote_link_out"},{"id":"pubmed:15994282","quote_policy":"short_quote_link_out"},{"id":"pubmed:16338616","quote_policy":"short_quote_link_out"},{"id":"pubmed:18022577","quote_policy":"short_quote_link_out"},{"id":"pubmed:19357394","quote_policy":"short_quote_link_out"},{"id":"pubmed:28380315","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:383d84","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1100402323421949957:08c7ef19-f617-4e5f-96c5-7c2c1c67703a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1139416045129617408:1598fcc0-b480-47d2-bea0-9ce2542e0f83","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1183071345787064321:6f6edab7-16de-4935-b96c-59658f1fcd45","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1230234974420393986:6b0bb658-7321-4d08-95df-73d7f4698396","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1240383883339870215:c1acfdc1-40d1-4074-9ad7-20cdf4187d5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1300546593909858304:756ef0a2-2e93-49d4-8157-f92d4c740428","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1364334295519809537:b9929f78-01af-4557-af02-47e0750f58bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1365932907123118080:f02d0f91-3729-41c1-9d38-30303c8d97b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1366378428568637441:cedbf061-6a9e-427b-a0b3-93719104f5a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1366721686314364937:fa9ba7a2-c595-4482-a827-42968cf91ca3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1366898683564949504:f87c18af-c495-490c-889f-1f1e24c37537","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1366938562185359364:0deaf818-cb1b-4a75-8d88-038f6059a3d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1376493355056590854:9c820d6a-0f2e-47a9-bd28-9a58e54d9391","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1376506057934049284:2d39d918-ccc3-44bc-8721-6e493cb25d62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1390043121044664320:b033f807-746f-405b-80ad-8ffb1d7b6874","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1404763365843472396:b1f75b00-946e-40aa-9baa-972332b7a515","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1416887868887343110:4a311c84-db50-4e9f-951b-972a9c9dab08","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1423288195408568325:a23bc49b-55ce-4d58-9eed-894e40af9453","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1446508256000712715:52ea1b25-7fc3-4fe8-8dac-9ac84d848ab0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1530211507002298368:9ab7d7fa-88aa-4bf0-a34d-14077923c202","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1591459397573939200:f130b844-feab-4e7d-a4a2-f79fcfae8dd6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1592208140623544321:9faffae5-5afc-4cb8-8462-a1bf3b7f7bfb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1639640135175139328:7550c1e3-958f-4eaf-bccf-89938ecfc11b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1652346431674408960:67390740-3739-486f-9cdb-758d55a6b17c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1695523353518596270:c76a1505-afd5-44fe-a059-cc3907dfc899","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866318813635162518:d7a8e063-e51e-420a-a19a-09395645a0a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1876646112817532928:bff8d30c-3667-4a3b-b41b-538dd463e54c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979226296887529985:76dcc2f7-a4b6-4dc9-a484-7b92c2b005ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2024458836325654891:00c74202-26d8-44d3-a63b-3d5d75b6ff43","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087918492557221965:1ae3e98b-8139-456a-86a4-c2e5604dacff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090408514166645003:c6eba2ee-cea4-4595-8ae2-9a2372bbab75","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:565922237912317954:c5a6139a-4453-439a-a65a-9c561d488126","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:645275625008173056:60c434f2-43e6-425a-9bda-130c92a59ae2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:674230023029698560:5086dbd2-b1f7-497b-bf7f-77f7cbcbb3b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:674777421569200128:3d685ce6-dfd9-47a1-aea2-8f920846a81b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:710066330737778688:dee881e0-3781-4621-a63f-ae975809664e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:835464706378825729:c5028522-fc17-4190-bdfa-d55b9ea72d2f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:974357757561393157:430d1e8b-7b92-49dd-9e93-af8fa7ec4050","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:974473902486315009:a5986cb5-89b6-4d6c-90a9-c259eba00ee7","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Uq-GfjbMDBU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:no3wTp30X_c","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":39,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":42},"count":42,"evidence_window":{"end":"2026-08-20","start":"2015-02-12"},"retrieval_snapshot":"2026-10-31T02:44:32.946885Z","timeline":[{"count":1,"week":"2015-W07"},{"count":1,"week":"2015-W38"},{"count":2,"week":"2015-W50"},{"count":1,"week":"2016-W11"},{"count":1,"week":"2017-W08"},{"count":2,"week":"2018-W11"},{"count":1,"week":"2019-W09"},{"count":1,"week":"2019-W24"},{"count":1,"week":"2019-W29"},{"count":1,"week":"2019-W41"},{"count":1,"week":"2020-W08"},{"count":1,"week":"2020-W12"},{"count":1,"week":"2020-W36"},{"count":2,"week":"2021-W08"},{"count":4,"week":"2021-W09"},{"count":2,"week":"2021-W13"},{"count":1,"week":"2021-W18"},{"count":1,"week":"2021-W24"},{"count":1,"week":"2021-W28"},{"count":1,"week":"2021-W31"},{"count":1,"week":"2021-W40"},{"count":1,"week":"2022-W21"},{"count":1,"week":"2022-W45"},{"count":1,"week":"2022-W46"},{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W17"},{"count":1,"week":"2023-W34"},{"count":1,"week":"2024-W08"},{"count":2,"week":"2024-W50"},{"count":1,"week":"2025-W02"},{"count":1,"week":"2025-W41"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W34"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: fludarabine and busulfan","status":"unmapped"},{"reason":"Unmapped registry intervention: fludarabine and melphalan","status":"unmapped"},{"reason":"Unmapped registry intervention: busulfan and fludarabine","status":"unmapped"},{"reason":"Unmapped registry intervention: busulfan and cyclophosphamide","status":"unmapped"},{"reason":"Unmapped registry intervention: cyclophosphamide and total body irradiation","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Leukemia, Myelocytic, Acute","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"BMT CTN 0901","aliases":["BMT CTN 0901","Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)","A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)"],"brief_title":"Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)","collaborators":["National Heart, Lung, and Blood Institute (NHLBI)","National Cancer Institute (NCI)","Blood and Marrow Transplant Clinical Trials Network","National Marrow Donor Program"],"conditions":["Leukemia, Myelocytic, Acute"],"display_condition":"acute myeloid leukemia or myelodysplastic syndrome","display_interventions":[["fludarabine","busulfan"],["fludarabine","melphalan"]],"enrollment":{"count":272,"type":"ACTUAL"},"interventions":[{"name":"Fludarabine and Busulfan","synonyms":["Fludara and Busulfex"],"type":"DRUG"},{"name":"Fludarabine and Melphalan","synonyms":["Fludara and Alkeran"],"type":"DRUG"},{"name":"Busulfan and Fludarabine","synonyms":["Busulfex and Fludara"],"type":"DRUG"},{"name":"Busulfan and Cyclophosphamide","synonyms":["Busulfex and Cytoxan"],"type":"DRUG"},{"name":"Cyclophosphamide and Total Body Irradiation","synonyms":["Cytoxan and radiation"],"type":"DRUG"}],"nct_id":"NCT01339910","official_title":"A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)","overall_status":"TERMINATED","phase":["PHASE3"],"primary_completion_date":{"date":"2017-01-16","type":"ACTUAL"},"primary_endpoints":[{"description":"Overall survival is defined as survival of death from any cause.","measure":"Percentage of Participants With Overall Survival (OS)","timeFrame":"18 months post-randomization"}],"registered_date":{"date":"2011-04-21","type":"ESTIMATED"},"registry_last_updated":"2023-01-04","registry_url":"https://clinicaltrials.gov/study/NCT01339910","short_name":"BMT CTN 0901","short_name_basis":"canonical_name","sponsor":"Medical College of Wisconsin","start_date":{"date":"2011-06","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"BMTCTN0901","type":"sponsor_study_id"},{"id":"U01HL069294","type":"nih"},{"id":"U01HL069294-05","type":"nih"},{"domain":"Blood and Marrow Transplant Clinical Trial Network","id":"BMT CTN 0901","type":"other"},{"id":"5U24CA076518","type":"nih"}],"study_type":"INTERVENTIONAL"}}}